Immunic, Inc. to Participate in Scientific and Investor Conferences in October

– Three Abstracts, Including One Late-Breaker, to be Presented on IMU-838, the Company’s Selective Oral DHODH Inhibitor, at the 37th Congress of ECTRIMS –

NEW YORK, September 28, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in October:

  • October 6-7: B &T Cell-Mediated Autoimmune Disease Drug Development Summit. Evelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present an overview of IMU-838. The presentation will be accessible on the “Events and Presentations” section of Immunic’s website at:
    • Title: IMU-838: A safe and potent inhibitor of DHODH for the treatment of autoimmune disease: mechanism of action and clinical outcomes
    • Session Title: Targeting B Cell Maturation, Depletion & Differentiation Factors
    • Date: Wednesday, October 6, 2021
    • Time: 12:30 PM ET
  • October 13-15: 37th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Three abstracts have been accepted for presentation, including a late-breaker on the company’s lead asset IMU-838. The poster presentations will be accessible on the “Events and Presentations” section of Immunic’s website at:

Late-Breaker Presentation:

    • Title: Relationship between neurofilament-light chain and disease activity in relapsing MS: observations from a phase 2 trial of IMU-838
    • Poster Number: P976
    • Authors: Robert J. Fox, Evelyn Peelen, Matej Ondrus, Andreas Muehler
    • Session Title: ep43 ePoster – Late Breaking News
    • Date: Wednesday, October 13, 2021 and Thursday, October 14, 2021
    • Time: 12:00 AM – 9:00 PM CET (6:00 AM – 3:00 PM ET)

Poster Presentations:

    • Title: IMU-838, a small molecule DHODH inhibitor in phase II clinical trial for multiple sclerosis, shows potent anti-EBV activity in cell-culture-based systems: Potential additional benefits in multiple sclerosis treatment
    • Poster Number: P372
    • Authors: Manfred Marschall, Evelyn Peelen, Regina Müller, Christina Wangen, Sabrina Wagner, Andreas Muehler, Manfred Gröppel, Daniel Vitt, Hella Kohlhof, Friedrich Hahn
    • Session Title: eP22 ePoster – Microbiology and virology
    • Date: Wednesday, October 13, 2021 and Thursday, October 14, 2021
    • Time: 12:00 AM – 9:00 PM CET (6:00 AM – 3:00 PM ET)
    • Title: Safety and tolerability of IMU-838, a next-generation DHODH inhibitor in EMPhASIS: a randomized, placebo-controlled phase 2 trial in relapsing multiple sclerosis
    • Poster Number: P645
    • Authors: Robert J. Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Muehler
    • Session Title: eP31 ePoster – Immunomodulation/Immunosuppression
    • Date: Wednesday, October 13, 2021 and Thursday, October 14, 2021
    • Time: 12:00 AM – 9:00 PM CET (6:00 AM – 3:00 PM ET)
  • October 19: Jefferies Next Generation IBD Therapeutics Summit 2021. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat. Specific details regarding timing, webcast and replay information will be published on the “Events and Presentations” section of Immunic’s website at:, once they are available.
  • October 25-28: BIO-Europe Digital. Members of Immunic’s business development and investor relations teams will participate in partnering activities at this conference. To schedule a meeting, please use the BIO-Europe partnering portal at:

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit:

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s participation in scientific and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 26, 2021, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at or Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 322 2216

US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910